Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort.
Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R, Rowe D, Schultz D, Edis R, Needham M, Macdonnell R, McCombe P, Birks C, Kiernan M. Talman P, et al. Among authors: mathers s. BMJ Open. 2016 Sep 30;6(9):e012054. doi: 10.1136/bmjopen-2016-012054. BMJ Open. 2016. PMID: 27694488 Free PMC article.
Natural history and clinical features of the flail arm and flail leg ALS variants.
Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, Willey E, Ampong MA, Ellis CM, Shaw CE, Al-Chalabi A, Leigh PN. Wijesekera LC, et al. Among authors: mathers s. Neurology. 2009 Mar 24;72(12):1087-94. doi: 10.1212/01.wnl.0000345041.83406.a2. Neurology. 2009. PMID: 19307543 Free PMC article.
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators. Cudkowicz ME, et al. Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Lancet Neurol. 2013. PMID: 24067398 Clinical Trial.
Motor neurone disease: progress and challenges.
Dharmadasa T, Henderson RD, Talman PS, Macdonell RA, Mathers S, Schultz DW, Needham M, Zoing M, Vucic S, Kiernan MC. Dharmadasa T, et al. Among authors: mathers s. Med J Aust. 2017 May 1;206(8):357-362. doi: 10.5694/mja16.01063. Med J Aust. 2017. PMID: 28446118 Review.
Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial.
Gold J, Rowe DB, Kiernan MC, Vucic S, Mathers S, van Eijk RPA, Nath A, Garcia Montojo M, Norato G, Santamaria UA, Rogers ML, Malaspina A, Lombardi V, Mehta PR, Westeneng HJ, van den Berg LH, Al-Chalabi A. Gold J, et al. Among authors: mathers s. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):595-604. doi: 10.1080/21678421.2019.1632899. Epub 2019 Jul 8. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 31284774 Free article.
Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).
Vucic S, Ryder J, Mekhael L, Rd H, Mathers S, Needham M, Dw S, Mc K; TEALS study group. Vucic S, et al. Among authors: mathers s. Medicine (Baltimore). 2020 Feb;99(6):e18904. doi: 10.1097/MD.0000000000018904. Medicine (Baltimore). 2020. PMID: 32028398 Free PMC article.
67 results